NICE | PharmaTimes
https://pharmatimes.com
in-depth news, features and insights for the pharmaceutical and healthcare sectorsThu, 10 Apr 2025 11:23:34 +0000en-US
hourly
1 https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.pngNICE | PharmaTimes
https://pharmatimes.com
3232232894315First treatment for common bladder cancer recommended by NICE
https://pharmatimes.com/news/first-treatment-for-common-bladder-cancer-recommended-by-nice/
Thu, 10 Apr 2025 11:22:53 +0000https://pharmatimes.com/?p=103110Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
]]>103110NICE recommends remote monitoring technology for heart failure patients
https://pharmatimes.com/news/nice-recommends-remote-monitoring-technology-for-heart-failure-patients/
Thu, 31 Oct 2024 13:00:08 +0000https://pharmatimes.com/?p=102540Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
]]>102540NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
https://pharmatimes.com/news/nice-recommends-santens-roclanda-to-treat-glaucoma-and-ocular-hypertension/
Mon, 21 Oct 2024 11:17:38 +0000https://pharmatimes.com/?p=102489Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK
]]>102489Theramex’s Eladynos recommended by NICE for post-menopausal bone disease
https://pharmatimes.com/news/theramexs-eladynos-recommended-by-nice-for-post-menopausal-bone-disease/
Tue, 20 Aug 2024 11:50:55 +0000https://pharmatimes.com/?p=102224Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause
]]>102224NICE nod for Darzalex with lenalidomide and dexamethasone
https://pharmatimes.com/news/nice_nod_for_darzalex_with_lenalidomide_and_dexamethasone_1500966/
Mon, 25 Sep 2023 13:11:00 +0000https://pharmatimes.com/uncategorized/nice_nod_for_darzalex_with_lenalidomide_and_dexamethasone_1500966/Therapy has been developed to treat adult patients with newly diagnosed multiple myeloma
]]>100096Bristol Myers Squibb’s Camzyos gets NICE recommendation
https://pharmatimes.com/news/bristol_myers_squibbs_camzyos_gets_nice_recommendation_1498299/
Wed, 06 Sep 2023 13:24:00 +0000https://pharmatimes.com/uncategorized/bristol_myers_squibbs_camzyos_gets_nice_recommendation_1498299/Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy
]]>100071Chiesi’s Elfabrio receives NICE recommendation
https://pharmatimes.com/news/chiesis_elfabrio_receives_nice_recommendation_1497860/
Mon, 04 Sep 2023 12:03:00 +0000https://pharmatimes.com/uncategorized/chiesis_elfabrio_receives_nice_recommendation_1497860/The therapy has been developed for the treatment of Fabry disease among adult patients
]]>100067NICE recommends Amryt’s Filsuvez for rare skin disorder
https://pharmatimes.com/news/nice_recommends_amryts_filsuvez_for_rare_skin_disorder_1496649/
Tue, 22 Aug 2023 12:14:00 +0000https://pharmatimes.com/uncategorized/nice_recommends_amryts_filsuvez_for_rare_skin_disorder_1496649/Around 670 people in England with epidermolysis bullosa will benefit from the treatment
]]>100050NICE gives green light for MSD’s Keytruda
https://pharmatimes.com/news/nice_gives_green_light_for_msds_keytruda_1496559/
Thu, 17 Aug 2023 16:33:00 +0000https://pharmatimes.com/uncategorized/nice_gives_green_light_for_msds_keytruda_1496559/The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
]]>100045NICE rejection for CSL Behring gene therapy
https://pharmatimes.com/news/nice_rejection_for_csl_behring_gene_therapy_1495841/
Fri, 04 Aug 2023 10:26:00 +0000https://pharmatimes.com/uncategorized/nice_rejection_for_csl_behring_gene_therapy_1495841/Therapy is a treatment option for adults with severe and moderately severe haemophilia B
